vTv Therapeutics (FRA:5VT0) Net Debt Paydown Yield % : -0.02% (As of Jul. 10, 2026)


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €29.60
GF Value €6,924.34
View Full Analysis

What is vTv Therapeutics Net Debt Paydown Yield %?

vTv Therapeutics FRA:5VT0 +1.37% 35 Net Debt Paydown Yield % is -0.02% as of Jul. 10, 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,924.34. Among 1,159 Biotechnology companies, vTv Therapeutics ranks worse than 55.13% on this metric.

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, vTv Therapeutics's Net Debt Paydown Yield % was -0.02%.


vTv Therapeutics  (FRA:5VT0) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


vTv Therapeutics Net Debt Paydown Yield % Related Terms


vTv Therapeutics Net Debt Paydown Yield % Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Net Debt Paydown Yield % Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Debt Paydown Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.16 0.37 0.82 0.91 0.03

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.86 0.15 0.03 -0.02

FRA:5VT0 vs SMNR, CNTB, ENLV: Net Debt Paydown Yield % Comparison

For the Biotechnology subindustry, vTv Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics Net Debt Paydown Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Net Debt Paydown Yield % falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Net Debt Paydown Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics Net Debt Paydown Yield % Calculation

vTv Therapeutics's Net Debt Paydown Yield % for the quarter that ended in Mar. 2026 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 0.18-0.19 )/123.6846
=-0.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

What does a Net Debt Paydown Yield % of -0.02% mean?
vTv Therapeutics (FRA:5VT0) has a Net Debt Paydown Yield % of -0.02% as of Jul. 10, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #639 out of 1159 companies in the Biotechnology industry, placing it in the top 55.1%.
Is vTv Therapeutics' Net Debt Paydown Yield % too high?
vTv Therapeutics' current Net Debt Paydown Yield % is -0.02%. Based on the distribution chart, vTv Therapeutics ranks #639 out of 1159 companies in the Biotechnology industry, which is below the industry midpoint. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Net Debt Paydown Yield % compare to SMNR and CNTB?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #639 out of 1159 companies for Net Debt Paydown Yield %. This places vTv Therapeutics in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on vTv Therapeutics and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current Net Debt Paydown Yield % is -0.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Net Debt Paydown Yield % of -0.02%. The stock's GF Value™ is €6,924.34, compared to a current price of €29.60 — trading 99.6% below its estimated fair value. The current Net Debt Paydown Yield % is -0.02%. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Net Debt Paydown Yield % is -0.02% as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €29.60 is trading 99.6% below its estimated GF Value™ of €6,924.34.

Key valuation signals for FRA:5VT0:

  • Net Debt Paydown Yield %: -0.02%
  • GF Value™: €6,924.34 vs. price of €29.60 (99.6% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.60
Price
€6,924.34
GF Value